コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 d lymphocyte-dependent colitis, seronegative ankylosing arthritis and enthesitis, conditions stereoty
2 ythematosus (1346+/-1011 pg per milliliter), ankylosing spondylitis (1368+/-1162 pg per milliliter),
3 improved significantly after MR imaging for ankylosing spondylitis (29% vs 80%, P < .001), undiffere
4 ren of women had an even higher incidence of ankylosing spondylitis (7.2 [1.5-34], p=0.013) than did
6 systemic lupus erythematosus (SLE) (n = 10), ankylosing spondylitis (AS) (n = 10), primary Sjogren's
8 s detailing their application in a number of ankylosing spondylitis (AS) and axial spondyloarthritis
9 mography (MDCT) findings of 41 patients with ankylosing spondylitis (AS) and compared them with pulmo
10 e autoimmune inflammatory arthritis disorder ankylosing spondylitis (AS) and with other related spond
12 ) affects approximately 40% of patients with ankylosing spondylitis (AS) but also affects patients wi
14 tients with MRI-evident sacroiliitis develop ankylosing spondylitis (AS) in the long term and whether
21 ment of spinal inflammation in patients with ankylosing spondylitis (AS) relies primarily on magnetic
22 udies of the HLA-B27-transgenic rat model of ankylosing spondylitis (AS) suggested that macrophages d
24 7 subtypes associated with susceptibility to ankylosing spondylitis (AS), and those reported not to b
25 HC) tag SNPs from 1,000 independent cases of ankylosing spondylitis (AS), autoimmune thyroid disease
26 s I molecule B27 is strongly associated with ankylosing spondylitis (AS), but the pathogenic role of
27 rated high heritability of susceptibility to ankylosing spondylitis (AS), it is only recently that th
28 ld standard of rheumatologists' diagnosis of ankylosing spondylitis (AS), psoriatic arthritis (PsA),
29 l and peripheral articular manifestations of ankylosing spondylitis (AS), psoriatic arthritis (PsA),
30 endoplasmic reticulum aminopeptidase 1) with ankylosing spondylitis (AS), which is restricted to HLA-
39 ciated with the chronic inflammatory disease Ankylosing Spondylitis (AS); however, the mechanisms und
42 = 8), juvenile rheumatoid arthritis (n = 3), ankylosing spondylitis (n = 1), and psoriatic spondylart
43 d IL12B regions convincingly associated with ankylosing spondylitis (P < 5 x 10(-8) in the combined d
44 tients with presumed sarcoidosis compared to ankylosing spondylitis (p = 0.0001), behcet's disease (p
45 ts with presumed sarcoidosis with respect to ankylosing spondylitis (p = 0.0001), behcet's disease, (
46 IBD), and psoriasis, psoriatic arthritis, or ankylosing spondylitis (psoriasis and spondyloarthropath
47 ges of patients achieving the Assessments in Ankylosing Spondylitis 20% response (ASAS20) at weeks 12
49 residues 528 and 575/725 is associated with ankylosing spondylitis among HLA-B27-positive individual
50 riteria for PsA, a new composite measure for ankylosing spondylitis and axial SpA, the ASDAS, new mea
52 dies of various physical therapy programs in ankylosing spondylitis and identify their benefits and p
53 has supported novel roles for these drugs in ankylosing spondylitis and in cancer prevention, accumul
54 ecent studies indicate that the morbidity of ankylosing spondylitis and PsA are considerably higher t
56 uding rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriasis, confirms the impor
59 of the tumor necrosis factor antagonists in ankylosing spondylitis and psoriatic arthritis has gener
60 necrosis factor inhibitors for patients with ankylosing spondylitis and psoriatic arthritis has had a
61 Sulfasalazine is moderately effective for ankylosing spondylitis and psoriatic arthritis, although
68 ole for HLA-B27 in genetic susceptibility to ankylosing spondylitis and related spondyloarthropathies
70 or rheumatoid arthritis, where patients with ankylosing spondylitis are offered therapy early in the
72 e for relieving the pain of axial disease in ankylosing spondylitis but these findings contradict two
73 me-wide association study in 2,053 unrelated ankylosing spondylitis cases among people of European de
75 changes in the course of the disease, Stoke Ankylosing spondylitis classification Spinal Score (SASS
76 oth M-CSF and MMP-3 correlated with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) v
77 onset, disease activity assessed by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),
78 ondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),
79 cal disease activity as measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),
80 Disease activity was assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
81 ter disease activity as measured by the Bath Ankylosing Spondylitis Disease Activity Index (P = 0.002
82 nthesitis (using the PsA-modified Maastricht Ankylosing Spondylitis Enthesitis Score [MASES] index).
83 ose with psoriatic arthritis, and those with ankylosing spondylitis from phase III trials of golimuma
84 al assessments included the BASDAI, the Bath Ankylosing Spondylitis Functional Index (BASFI), the Ank
85 ght, VAS scores for entheseal pain, the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bat
87 nal limitations were assessed using the Bath Ankylosing Spondylitis Functional Index (BASFI; score ra
88 etween inflammation and structural damage in ankylosing spondylitis has been an important focus of re
90 ive arthritis, but an infectious trigger for ankylosing spondylitis has not yet been established.
91 d for patients with rheumatoid arthritis and ankylosing spondylitis have been reported, and generic q
94 that TNFi slows radiographic progression in ankylosing spondylitis in data from clinical trials may
97 f Life (ASQoL) instrument, the ASsessment in Ankylosing Spondylitis International Working Group crite
102 IL-1A association further substantiate that ankylosing spondylitis is determined to a large extent b
103 modified New York criteria, the diagnosis of ankylosing spondylitis is made based on the presence of
106 autoimmune disease and evidence showed that ankylosing spondylitis may be a microbiome-driven diseas
108 shown to be differentially abundant between ankylosing spondylitis patients and healthy controls.
113 ng Spondylitis Functional Index (BASFI), the Ankylosing Spondylitis Quality of Life (ASQoL) instrumen
114 the Short Form 36 (SF-36) Health Survey and Ankylosing Spondylitis Quality of Life (ASQoL) Questionn
115 tis Disease Activity Index (BASDAI), and the Ankylosing Spondylitis Quality of Life (ASQoL) questionn
116 lvis, and hips were scored by using the Bath Ankylosing Spondylitis Radiology Index (BASRI) by an exp
117 pinal radiographs were scored using the Bath Ankylosing Spondylitis Radiology Index for the spine (BA
118 dy reports four genetic loci associated with ankylosing spondylitis risk and identifies a major role
119 before HLA class I presentation, only affect ankylosing spondylitis risk in HLA-B27-positive individu
122 of the interleukin-1 (IL-1) region genes in ankylosing spondylitis suggested the susceptibility to b
123 A recent meta-analysis of published scans of ankylosing spondylitis susceptibility has confirmed site
124 on-major histocompatibility complex genes in ankylosing spondylitis susceptibility, and suggests area
126 nt GWAS on multiple sclerosis, psoriasis and ankylosing spondylitis that inclusion of known covariate
127 ide strong evidence that HLA-B27 operates in ankylosing spondylitis through a mechanism involving abe
128 Exercise therapy should remain a mainstay of ankylosing spondylitis treatment complementing medical t
129 durations may result in a paradigm shift for ankylosing spondylitis treatment similar to that undergo
131 50% and 75% of patients were diagnosed with ankylosing spondylitis were ascertained from a database
132 Forty patients with active, inflammatory ankylosing spondylitis were randomly assigned to receive
133 cantly reduces spinal inflammation in active ankylosing spondylitis when compared to placebo; there w
134 esitis-related arthritis progress to develop ankylosing spondylitis within 10 years after presentatio
136 e SpA (2 with psoriatic arthritis and 1 with ankylosing spondylitis) were isolated by positive select
137 une hemolytic anemia, pernicious anemia, and ankylosing spondylitis), infectious (pneumonia, hepatiti
138 relationship between the gut microbiome and ankylosing spondylitis, a quantitative metagenomics stud
139 Evaluating Long-Term Efficacy and Safety in Ankylosing Spondylitis, a randomized controlled study, w
141 anding inflammation in rheumatoid arthritis, ankylosing spondylitis, and juvenile chronic arthritis.
142 tion may have structure-modifying effects in ankylosing spondylitis, and may thereby alter the diseas
143 immune diseases such as behcet's disease and ankylosing spondylitis, and ocular involvement of infect
144 nvestigated one in detail, a risk allele for ankylosing spondylitis, and provide direct evidence of a
145 py not only in RA but also in Crohn disease, ankylosing spondylitis, and several other chronic inflam
146 lgia rheumatica (PMR), giant cell arteritis, ankylosing spondylitis, and Sjogren's syndrome, and to p
147 e of the spondyloarthritides, including PsA, ankylosing spondylitis, and the broader categories of Sp
148 the disease-modifying role of these drugs in ankylosing spondylitis, and their use in the understudie
149 s, two patients with gout, two patients with ankylosing spondylitis, and two patients with psoriatic
151 h American sample of two new loci related to ankylosing spondylitis, ARTS1 and IL23R, and confirmatio
152 a prospective study involving patients with ankylosing spondylitis, behcet's disease, presumed sarco
153 eously investigated the genetic landscape of ankylosing spondylitis, Crohn's disease, psoriasis, prim
154 0 patients and 45 controls: alopecia areata, ankylosing spondylitis, dermatomyositis, Graves' disease
155 ce of rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, familial Mediterranean fever, an
157 principle has relevance to diseases such as ankylosing spondylitis, in which HLA-B27 and ERAP jointl
158 , rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-infectious uveitis, and mult
159 d arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, or inflammatory bowel disease us
160 e advances in the pharmacological therapy of ankylosing spondylitis, physical therapy remains an esse
161 carrying of the spinal cord in the course of ankylosing spondylitis, present in MRI include: bone mar
162 n the pathogenesis or development process of ankylosing spondylitis, providing new leads for the deve
163 Group criteria for SpA, without evidence of ankylosing spondylitis, psoriasis, inflammatory bowel di
164 ct in the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and juvenil
165 ts and for diseases other than RA, including ankylosing spondylitis, psoriatic arthritis, and polymyo
166 uded in the category of spondyloarthropathy (ankylosing spondylitis, psoriatic arthritis, reactive ar
167 ry rheumatic diseases that primarily include ankylosing spondylitis, reactive arthritis, and the arth
168 rheumatological conditions (i.e. psoriasis, ankylosing spondylitis, rheumatoid arthritis, fibromyalg
169 able and effective structure modification in ankylosing spondylitis, the data strongly suggest a bene
173 atibility complex genes in predisposition to ankylosing spondylitis, which will be summarized here.
174 and women differ in their susceptibility to ankylosing spondylitis, with about 2.5 men affected for
175 de over 90% of the overall susceptibility to ankylosing spondylitis, with about half of the genetic c
176 with unlike conformations in differentially ankylosing spondylitis-associated subtypes) must not be
207 rmatomyositis; 16 had scleroderma; eight had ankylosing spondylitis; five had juvenile RA; three had
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。